Abbott Laboratories has announced plans to acquire Ibis Biosciences, the molecular diagnostics division of Isis Pharmaceuticals. Abbott invested $40 million in the company earlier this year, and will purchase all remaining equity for $175 million.
Wyeth Pharmaceuticals has announced the acquisition of Thiakis Limitied, a privately held biotech based in the UK. Thiakis lead product candidate, TKS 1225, will potentially treat obesity and other co-morbidities.
New England-based pharma research firm Charles River Laboratories will invest $20 million and create 60 jobs by expanding its Charleston, SC, operations.
